| 產(chǎn)品編號 | bs-12143R |
| 英文名稱 | Rabbit Anti-SHANK3 antibody |
| 中文名稱 | 富含脯氨酸突觸相關(guān)蛋白SHANK3抗體 |
| 別 名 | KIAA1650; Proline rich synapse associated protein 2; Proline-rich synapse-associated protein 2; ProSAP2; PSAP2; SH3 and multiple ankyrin repeat domains 3; SH3 and multiple ankyrin repeat domains protein 3; SH3/ankyrin domain gene 3; SHAN3_HUMAN; Shank postsynaptic density protein; Shank3; Shank3b; SPANK 2; SPANK2. |
 |
Specific References (2) | bs-12143R has been referenced in 2 publications.
[IF=3.052] Burcu Acikgoz. et al. Gender differences in effects of prenatal and postnatal exposure to electromagnetic field and prenatal zinc on behaviour and synaptic proteins in rats. J Chem Neuroanat. 2022 Jul;122:102092 IHC ; Rat.
[IF=2.948] Nevin Ersoy. et al. The Effects of Prenatal and Postnatal Exposure to 50-Hz and 3 mT Electromagnetic Field on Rat Testicular Development. MED LITH. 2023 Jan;59(1):71 IHC ; Rat.
|
| 研究領(lǐng)域 | 細胞生物 神經(jīng)生物學 通道蛋白 細胞粘附分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Rat (predicted: Human,Mouse,Pig,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 186kDa |
| 細胞定位 | 細胞漿 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human SHANK3: 1151-1250/1741 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
SH3 and multiple ankyrin repeat domains 1-3 (Shank1-3) of the Shank/ProSAP family are molecular scaffolds in the postsynaptic density (PSD). The PSD is an electron-dense structure underneath the postsynaptic plasma membrane of excitatory synapses that anchors and clusters glutamate receptors opposite to the presynaptic neurotransmitter release site. Shank proteins contain PDZ modular domains that coordinate the synaptic localization of ion channels, receptors, signaling enzymes, and cell adhesion molecules. The PDZ domain mediates protein-protein interactions via the recognition of a conserved sequence motif at the C-terminus of their target protein(s). Shank recruits betaPIX and PAK to spines to regulate postsynaptic structure and interacts with NMDA receptor and metabotropic glutamate receptor complexes. Transcript splice variation in the Shank family influences the spectrum of Shank-interacting proteins in the PSDs of adult and developing brain to ensure normal development. Function: Seems to be an adapter protein in the postsynaptic density (PSD) of excitatory synapses that interconnects receptors of the postsynaptic membrane including NMDA-type and metabotropic glutamate receptors via complexes with GKAP/PSD-95 and Homer, respectively, and the actin-based cytoskeleton. May play a role in the structural and functional organization of the dendritic spine and synaptic junction. Subunit: May homomultimerize via its SAM domain (By similarity). Interacts with DLGAP1/GKAP, MGLUR1A, MGLUR5 C-termini via its PDZ domain (By similarity). Interacts with HOMER1, HOMER2, HOMER3 and CTTN/cortactin SH3 domain (By similarity). Is part of a complex with DLG4/PSD-95 and DLGAP1/GKAP. Interacts with DBNL. Interacts (via PDZ domain) with PROSAPIP1 (via C-terminus) (By similarity). Interacts with BAIAP2. Subcellular Location: Cytoplasm (By similarity). Cell junction, synapse (By similarity). Cell junction, synapse, postsynaptic cell membrane, postsynaptic density (By similarity). Note=Postsynaptic density of neuronal cells (By similarity). Tissue Specificity: Expressed in the cerebral cortex and the cerebellum. DISEASE: Defects in SHANK3 are the cause of schizophrenia type 15 (SCZD15) [MIM:613950]. SCZD15 is a complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder. Similarity: Contains 6 ANK repeats. Contains 1 PDZ (DHR) domain. Contains 1 SAM (sterile alpha motif) domain. Contains 1 SH3 domain. SWISS: Q9BYB0 Gene ID: 85358 Database links: Entrez Gene: 85358 Human Entrez Gene: 58234 Mouse Omim: 606230 Human SwissProt: Q9BYB0 Human SwissProt: Q4ACU6 Mouse Unigene: 149035 Human Unigene: 146855 Mouse Unigene: 42876 Rat |
| 產(chǎn)品圖片 |
Paraformaldehyde-fixed, paraffin embedded (rat brain); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (SHANK3) Polyclonal Antibody, Unconjugated (bs-12143R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-SHANK3 Polyclonal Antibody, Unconjugated(bs-12143R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
